Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial

KF. Pan, WQ. Li, L. Zhang, WD. Liu, JL. Ma, Y. Zhang, K. Ulm, JX. Wang, L. Zhang, M. Bajbouj, LF. Zhang, M. Li, M. Vieth, M. Quante, LH. Wang, S. Suchanek, R. Mejías-Luque, HM. Xu, XH. Fan, X. Han, ZC. Liu, T. Zhou, WX. Guan, RM. Schmid, M....

. 2024 ; 30 (11) : 3250-3260. [pub] 20240730

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003712
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 39079993
DOI 10.1038/s41591-024-03153-w
Knihovny.cz E-zdroje

Gastric cancer is a leading cause of cancer-related deaths in China. Affecting more than 40% of the world's population, Helicobacter pylori is a major risk factor for gastric cancer. While previous clinical trials indicated that eradication of H. pylori could reduce gastric cancer risk, this remains to be shown using a population-based approach. We conducted a community-based, cluster-randomized, controlled, superiority intervention trial in Linqu County, China, with individuals who tested positive for H. pylori using a 13C-urea breath test randomly assigned to receiving either (1) a 10-day, quadruple anti-H. pylori treatment (comprising 20 mg of omeprazole, 750 mg of tetracycline, 400 mg of metronidazole and 300 mg of bismuth citrate) or (2) symptom alleviation treatment with a single daily dosage of omeprazole and bismuth citrate. H. pylori-negative individuals did not receive any treatment. We examined the incidence of gastric cancer as the primary outcome. A total of 180,284 eligible participants from 980 villages were enrolled over 11.8 years of follow-up, and a total of 1,035 cases of incident gastric cancer were documented. Individuals receiving anti-H. pylori therapy showed a modest reduction in gastric cancer incidence in intention-to-treat analyses (hazard ratio 0.86, 95% confidence interval 0.74-0.99), with a stronger effect observed for those having successful H. pylori eradication (hazard ratio 0.81, 95% confidence interval 0.69-0.96) than for those who failed treatment. Moderate adverse effects were reported in 1,345 participants during the 10-day treatment. We observed no severe intolerable adverse events during either treatment or follow-up. The findings suggest the potential for H. pylori mass screening and eradication as a public health policy for gastric cancer prevention. Chinese Clinical Trial Registry identifier: ChiCTR-TRC-10000979 .

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003712
003      
CZ-PrNML
005      
20250206104633.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41591-024-03153-w $2 doi
035    __
$a (PubMed)39079993
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pan, Kai-Feng $u State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China. pan-kf@263.net $1 https://orcid.org/0000000236803126
245    10
$a Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial / $c KF. Pan, WQ. Li, L. Zhang, WD. Liu, JL. Ma, Y. Zhang, K. Ulm, JX. Wang, L. Zhang, M. Bajbouj, LF. Zhang, M. Li, M. Vieth, M. Quante, LH. Wang, S. Suchanek, R. Mejías-Luque, HM. Xu, XH. Fan, X. Han, ZC. Liu, T. Zhou, WX. Guan, RM. Schmid, M. Gerhard, M. Classen, WC. You
520    9_
$a Gastric cancer is a leading cause of cancer-related deaths in China. Affecting more than 40% of the world's population, Helicobacter pylori is a major risk factor for gastric cancer. While previous clinical trials indicated that eradication of H. pylori could reduce gastric cancer risk, this remains to be shown using a population-based approach. We conducted a community-based, cluster-randomized, controlled, superiority intervention trial in Linqu County, China, with individuals who tested positive for H. pylori using a 13C-urea breath test randomly assigned to receiving either (1) a 10-day, quadruple anti-H. pylori treatment (comprising 20 mg of omeprazole, 750 mg of tetracycline, 400 mg of metronidazole and 300 mg of bismuth citrate) or (2) symptom alleviation treatment with a single daily dosage of omeprazole and bismuth citrate. H. pylori-negative individuals did not receive any treatment. We examined the incidence of gastric cancer as the primary outcome. A total of 180,284 eligible participants from 980 villages were enrolled over 11.8 years of follow-up, and a total of 1,035 cases of incident gastric cancer were documented. Individuals receiving anti-H. pylori therapy showed a modest reduction in gastric cancer incidence in intention-to-treat analyses (hazard ratio 0.86, 95% confidence interval 0.74-0.99), with a stronger effect observed for those having successful H. pylori eradication (hazard ratio 0.81, 95% confidence interval 0.69-0.96) than for those who failed treatment. Moderate adverse effects were reported in 1,345 participants during the 10-day treatment. We observed no severe intolerable adverse events during either treatment or follow-up. The findings suggest the potential for H. pylori mass screening and eradication as a public health policy for gastric cancer prevention. Chinese Clinical Trial Registry identifier: ChiCTR-TRC-10000979 .
650    _2
$a lidé $7 D006801
650    12
$a nádory žaludku $x prevence a kontrola $x epidemiologie $x mikrobiologie $7 D013274
650    12
$a infekce vyvolané Helicobacter pylori $x farmakoterapie $x epidemiologie $x mikrobiologie $7 D016481
650    12
$a Helicobacter pylori $x účinky léků $7 D016480
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a omeprazol $x terapeutické užití $x aplikace a dávkování $7 D009853
650    _2
$a dospělí $7 D000328
650    _2
$a antibakteriální látky $x terapeutické užití $x aplikace a dávkování $7 D000900
650    _2
$a senioři $7 D000368
650    _2
$a metronidazol $x terapeutické užití $x aplikace a dávkování $7 D008795
650    _2
$a tetracyklin $x terapeutické užití $x aplikace a dávkování $7 D013752
650    _2
$a organokovové sloučeniny $x terapeutické užití $x aplikace a dávkování $7 D009942
651    _2
$a Čína $x epidemiologie $7 D002681
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Li, Wen-Qing $u State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China. wenqing_li@bjmu.edu.cn $1 https://orcid.org/0000000283365552
700    1_
$a Zhang, Lian $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Liu, Wei-Dong $u Health Bureau of Linqu County, Weifang, China
700    1_
$a Ma, Jun-Ling $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Zhang, Yang $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Ulm, Kurt $u School of Medicine and Health, Technical University of Munich, Munich, Germany
700    1_
$a Wang, Jian-Xi $u Health Bureau of Linqu County, Weifang, China
700    1_
$a Zhang, Lei $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Bajbouj, Monther $u School of Medicine and Health, Technical University of Munich, Munich, Germany
700    1_
$a Zhang, Lan-Fu $u Health Bureau of Linqu County, Weifang, China
700    1_
$a Li, Ming $u Health Bureau of Linqu County, Weifang, China
700    1_
$a Vieth, Michael $u Institute of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg, Klinikum Bayreuth, Bayreuth, Germany
700    1_
$a Quante, Michael $u School of Medicine and Health, Technical University of Munich, Munich, Germany $u Freiburg: Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg, Germany
700    1_
$a Wang, Le-Hua $u Health Bureau of Linqu County, Weifang, China
700    1_
$a Suchanek, Stepan $u Department of Medicine & Department of Gastrointestinal Oncology, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
700    1_
$a Mejías-Luque, Raquel $u School of Medicine and Health, Technical University of Munich, Munich, Germany $1 https://orcid.org/0000000246024927
700    1_
$a Xu, Heng-Min $u State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Fan, Xiao-Han $u State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Han, Xuan $u State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Liu, Zong-Chao $u State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Zhou, Tong $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Guan, Wei-Xiang $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China
700    1_
$a Schmid, Roland M $u School of Medicine and Health, Technical University of Munich, Munich, Germany
700    1_
$a Gerhard, Markus $u School of Medicine and Health, Technical University of Munich, Munich, Germany. markus.gerhard@tum.de $1 https://orcid.org/0000000191103950
700    1_
$a Classen, Meinhard $u School of Medicine and Health, Technical University of Munich, Munich, Germany
700    1_
$a You, Wei-Cheng $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China. weichengyou2022@outlook.com $1 https://orcid.org/000900075426609X
773    0_
$w MED00003459 $t Nature medicine $x 1546-170X $g Roč. 30, č. 11 (2024), s. 3250-3260
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39079993 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104629 $b ABA008
999    __
$a ok $b bmc $g 2263465 $s 1239719
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 11 $d 3250-3260 $e 20240730 $i 1546-170X $m Nature medicine $n Nat Med $x MED00003459
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace